Effect of rifampicin isoniazid on the steady state pharmacokinetics of moxifloxacin

摘要

Background & objectives:Moxifloxacin (MFX) is reported to have promising antimycobacterial activity, and has a potential to shorten tuberculosis (TB) treatment. We undertook this study to examine the influence of rifampicin (RMP) and isoniazid (INH) on the steady state pharmacokinetics of MFX individually in healthy individuals.